Youth advised to stay away from narcotics
Speaking on the occassion, SETKUR CEO Dr K Venugopal emphasised that many youngsters are falling into the trap of drug addiction either due to peer pressure or mental stress. He warned that selfish individuals are discreetly introducing drugs into schools and colleges, and although drugs may initially create a sense of joy and excitement, they soon lead to mental distress, compelling the user to crave repeated consumption.
Dr Venugopal used a Power Point presentation to explain the harmful effects of drug abuse. He stated that oral consumption damages the digestive system and liver, smoking affects the lungs and heart, and injecting drugs increases the risk of life-threatening diseases like hepatitis and HIV.
He strongly urged the youth to stay away from narcotics and to be aware of their severe physical and psychological repercussions.
Inspector Vishwanath, who also addressed the seminar, remarked that drugs can completely ruin a person both mentally and physically. They alter one's behaviour and conduct, often leading to criminal activities to fund the addiction. He informed the students that if they witness any illegal drug-related activities in their surroundings, they should immediately report them to the toll-free helpline number 1972. He added that both Central and State governments have established a special police division named Eagle to combat drug trafficking and ensure community safety.
College Principal Venu Gopal Sharma emphasised the crucial role of parental supervision in preventing drug abuse among students. He advised parents to regularly observe their children's behaviour and to act promptly if any suspicious changes are noticed. SETKURU supervisor Shyam Babu, along with college faculty members, also participated in the programme. Students were encouraged to download and utilise the Disha App for their safety and support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
US Health Secretary Kennedy to oust members of US preventive task force
Bengaluru: Health Secretary Robert F. Kennedy Jr. is planning to remove all the members of an advisory panel that determines what cancer screenings and other preventive health measures insurers must cover, the Wall Street Journal reported on Friday, citing people familiar with the matter. Kennedy plans to dismiss all 16 panel members of the U.S. Preventive Services Task Force , according to the WSJ report. This is the latest in a series of far-reaching actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine. In June, Kennedy dismissed all 17 members of the Advisory Committee on Immunization Practices (ACIP), replacing them with eight new members including known vaccine skeptics. The USPSTF includes medical experts serving four-year terms on a volunteer basis and has a major role in choosing what services will be covered under the 2010 Affordable Care Act , also known as Obamacare. The U.S. Supreme Court in June upheld the constitution of the task force and ruled in favor of its recommendation to cover preventive care such as cancer screenings and HIV prevention medication at no cost to patients. Its members are selected by the U.S. Secretary of Health and Human Services without Senate confirmation.
The Hindu
8 hours ago
- The Hindu
Lenacapavir: After FDA approval, HIV pre-exposure prophylaxis injectable moving closer to EU approval
On July 25, The European Medicines Agency (EMA)'s advisory committee recommended Gilead Sciences' Lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. Any recommendation by EMA's advisory committee has to be formally approved by the European Commission, which is expected later this year. The recommendation by the EMA's advisory committee comes about a month after the U.S. FDA on June 18, 2025 approved the injectable HIV-1 capsid inhibitor as a pre-exposure prophylaxis (PrEP). The World Health Organization welcomed the approval by FDA on June 19 and issued guidelines for use of Lenacapavir for HIV prevention on July 14. 'Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer,' the guidelines say. Studies have also shown that Lenacapavir can achieve significant viral suppression, even in cases where other drugs have failed. The FDA approved Lenacapavir is based on the 2024 results from the PURPOSE 1 and PURPOSE 2 trials, which demonstrated the safety and efficacy of the pre-exposure prophylaxis injectable across diverse populations and settings. The PURPOSE 1 was a Phase 3, double-blind, randomised trial to evaluate the safety and efficacy of twice-yearly, subcutaneous Lenacapavir for pre-exposure prophylaxis (PrEP) and was tested on 5,338 cisgender women and adolescent girls aged 16-25 across 25 sites in South Africa and three sites in Uganda. The injectable was compared with an active control arm that received once-daily oral pre-exposure prophylaxis drug Truvada (emtricitabine-tenofovir disoproxil fumarate; F/TDF). There were zero HIV infections among 2,134 participants in the Lenacapavir group, while the active control group had 39 infections among 2,136 participants. In the PURPOSE 2 Phase-3 trial involving 3,265 participants in the modified intention-to-treat analysis, two participants were infected with HIV in the arm that received the injectable, while nine participants who received the active control PrEP oral drug Truvada (emtricitabine-tenofovir disoproxil fumarate; F/TDF) were infected. The background HIV incidence in the screened population (4,634 participants) was 2.37 per 100 person-years. The trial was carried out in of cisgender men, transgender, and nonbinary individuals across 88 sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the U.S. Compared with the generic PrEP oral drug Truvada, which is extremely inexpensive and widely available, Lenacapavir costs $28,000 for two injections. Why would people ever prefer to use Lenacapavir considering the cost? 'Oral PrEP will be effective only if there is 100% adherence. The oral drug won't work even if it is missed for a day because the drug level will be only 24 hours,' says Dr. N. Kumarasamy, Chief and Director, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai. 'People who have the highest risk such as sex workers and gay men have to take the drug every day. Taking a tablet every day, even for a deceased patient, is so difficult. They tend to miss a dose, which is why adherence is never 100%,' he says. 'Even in the case of on-demand PrEP, where people who want to indulge in unprotected sex have to take the oral drug two days before, then throughout the period of risky behaviour and continue for two more days after risky behaviour ends, adherence never goes beyond 85-90%. PrEP will work only if the adherence is 100%.' According to Dr. Kumarasamy, despite the oral tablet being inexpensive and easy to take, the adherence is less than ideal, the reason why people are moving towards long-acting injectables that prevent HIV infection for months after an injection. Cabotegravir, which was developed as pre-exposure prophylaxis (PrEP), underwent trials in many countries and was approved for use. Cabotegravir, which is administered intramuscularly every two months, was found superior compared with every day oral PrEP tablet, and started getting implemented in certain parts of the world, Dr. Kumarasamy says. 'Since Cabotegravir has to be administered every two months, people tend to forget. The new drug Lanacapivir has been found to be effective for six months in the trials. The injectable was developed in 2021 as treatment in people who no longer respond to other drugs as they have developed resistance,' he says. Because Lenacapavir was found to be long-acting, it was repurposed as a pre-exposure prophylaxis administered subcutaneously. 'Lenacapavir is a robust molecule and is the best solution in the absence of vaccines. Even if there is going to be an HIV vaccine one day, I'm sure people will have to take the vaccine every year or something. Like a flu shot, you know if at all they are going to develop a vaccine, people may have to take it every year or every six months as a booster dose. It may not be like a one dose that is effective for years,' Dr. Kumarasamy says. 'In the absence of a HIV vaccine, I think the pre-exposure prophylaxis every six months can be considered like a vaccine.' Gilead is developing the same molecule to be administered once a year instead of every six months. They are already working on that. But it will not be a subcutaneous form but as an intramuscular injection, he says. Licensing agreements On October 2, 2024, Gilead Sciences signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic Lenacapavir. Of the six generic manufacturers, four are in India. Besides signing agreement to license generic manufacturers to make the injectable, Gilead Sciences also said that it would 'support low-cost access to the drug in high-incidence, resource-limited countries at no profit until generic manufacturers are able to fully support demand'. These countries are: Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe. The company has licensed Dr. Reddy's Laboratories Limited, Emcure, Hetero and Mylan, a subsidiary of Viatris, to manufacture Lenacapavir in India. The companies will be permitted to supply to 120 countries. According to the press release, the agreements cover not only Lenacapavir for HIV prevention but also for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. According to Dr. Kumarasamy one company has already started developing the drug and Lenacapavir may become available next year once the Indian drug regulator approves it based on the results of a safety study carried out in India. As per his estimate, the generic form of Lenacapavir will cost about $100 per dose.
India Today
12 hours ago
- India Today
From death certificate to marriage certificate: Journey of HIV-positive Indians
Tarun (name changed), a Mumbai resident, was diagnosed HIV-positive and was only given 30 days to live. He defied the prognosis, and has been living with the virus for 23 years now. But back in 2002, the news that someone had tested positive for HIV was nothing short of a death before the virus killed, social rejection and emotional distress killed those with has been leading a near-normal life for 23 years, thanks to advancements in antiretroviral therapy (ART), family support and peer individuals now have a lifespan that is close to that of uninfected people. It is now, more than ever, that they are seeking companionship for the long now 46, is healthy, married, and living what he calls "a full life". His wife, Anushka (name changed), is also HIV-positive. Together, they are parents to a biological daughter, who is HIV-negative, and an adopted must be noted that India had an estimated 23.48 lakh people living with the virus in 2019 – the third-highest burden of HIV in the world – according to a National AIDS Control Organisation (Naco) India Today Digital spoke to said the country today has around 2.5-3 million HIV-positive people, roughly a third of whom fall in the marriage bracket of 21-35 years."Today, more HIV-positive people are getting married compared to a decade ago," Anjali Gopalan, founder and executive director of The Naz Foundation (India) Trust, told India Today Digital."HIV-positive individuals are now even marrying HIV-negative people," said Gopalan, whose organisation has extensively worked with issues related to HIV/AIDS and sexuality for over three MK, advocacy officer with Mumbai-based Humsafar Trust, a support group for people living with HIV (PLHIV), also said that marriages among HIV-positive people are on the rise as compared to a decade HIV-positive individuals, even the way of finding partners is seemingly online matrimony platforms like and have emerged. Matrimony major recently launched a section for HIV-positive brides and experts and HIV-positive individuals told India Today Digital that most people from the community seeking partners do so offline, primarily through annual meet-ups organised by Naco. Experts said even the World Health Organisation (WHO) plays a small role in the the coming up of online matrimonial platforms and Jeevansathi's exclusive section is a signal of a positive shift in India's HIV/AIDS JOURNEY FROM DEATH CERTIFICATE TO MARRIAGE CERTIFICATETarun, a chef returning from a cruise-liner job, was diagnosed with HIV during a routine check-up in and scared, he hid the diagnosis from his mother for nine months. By the time she found out, the doctor had given him 30 days to live. But his mother's support kept him he stuck to medication, a healthier lifestyle and diet, and regular check-ups, Tarun's immunity and outlook improved. He left his job as a chef, fearing a simple kitchen injury could stir a panic about HIV transmission, and took up work at a call centre years passed, he became a peer counsellor day, he was asked to speak with an HIV-positive woman from Raipur who had faced abuse from her in-laws after losing her husband to AIDS. He didn't expect that this woman, by the end of counselling, would become his friend, and ultimately his might have found his life partner by chance while counselling, but most HIV-positive people find their spouses either at meet-ups or the matrimonial sites that have come COUPLES AND SAFE CHILDBIRTHThe journey of Tarun and Anushka, both HIV-positive individuals, helps us understand some of the struggles that such couples marriage, childbirth is where they faced the next big challenge."When we planned to have a baby, many hospitals turned us away because we were both HIV-positive," Tarun said. "The discrimination came from everyone – receptionists, ward boys, nurses, and even doctors."The couple were wrongly told they couldn't have an HIV-negative child."If the mother is HIV-positive, she is placed on lifelong antiretroviral therapy (ART) to suppress the virus to undetectable levels. With proper adherence, this reduces the risk of transmission to the baby to less than 1%," Dr Rashmi Singh, a Delhi-based medicine specialist, told India Today Digital."During childbirth, if the mother's viral load is under control, a vaginal delivery is also considered safe, but just to be sure, most gynaecologists recommend a C-section delivery," she the process after the baby is delivered, Singh said, "After birth, the infant is given preventive medication for several weeks, and is monitored through regular HIV testing up to 18 months of age."In cases where only the father is HIV-positive, Singh added, "Assisted reproductive technologies such as sperm washing followed by intrauterine insemination (IUI) or in vitro fertilisation (IVF) can be used. These methods ensure that the virus is not present in the sperm used for conception, preventing transmission to both the mother and child."MANAGING HIV WITHIN A MARRIAGEHowever, couples with HIV need to be extra careful about unprotected sex even if both are living with the told India Today Digital that he and his wife planned their pregnancy under the close supervision of a gynaecologist, as he cannot have regular unprotected sex despite having his viral load under control. His semen could still affect his wife's CD4 count – a key indicator of immune health in people living with today, with ART, many people can restore and maintain normal CD4 Tarun's case, regular monitoring of both viral load and CD4 count helped guide safe family must also be noted that India's ART programme is one of the world's most cost-effective and accessible. First-line ART medicines can cost around Rs 1,500-Rs 2,000 per month at private institutions, but under Naco, the government provides them free of WITH HIV: BEYOND THE VIRAL LOADDespite being cost-effective today and offering a high chance of leading a normal life, living with HIV within a relationship still comes with its own set of emotional and practical serodiscordant couples, where only one partner is HIV-positive, the HIV-negative partner may have to make certain adjustments, especially around trust and physical intimacy, such as barely being able to have unprotected sex, and other lifestyle adjustments involving Foundation's Anjali Gopalan said, "When there is openness and honesty about one's HIV status, many couples are able to make it work. With the right support and counselling, people often choose to focus on the relationship and the bond they share, rather than the condition."Finding a partner, however, remains one of the biggest MK of the Humsafar Trust points out, "Most people living with HIV try to find a partner who is also HIV positive. Though marriage rates have improved, the success rate at community HIV melawas (fair, in Marathi) is still just 1-2%."Melawas are the Naco-organised community meet-ups held in Maharashtra. Similar meet-ups, known by different local names, are held annually in cities across India. Experts say these are typically low-key events, drawing around 100–150 attendees now married and actively involved in the HIV-positive community as a counsellor, says he attends the melawa across Maharashtra, to connect with others and offer common way people intending to get married meet is through word-of-mouth, especially via counsellors who interact with people living with HIV and often pass along information when they hear someone is looking for a partner."I have helped four couples get married by informally playing matchmaker," Tarun told India Today who has attended nearly every community meet-up in Maharashtra in the past several years, said, "Around 80% of those who turn up at these events are men. This gender disparity is one of the reasons why the success rate of melawas leading to marriage remains so low."Both Sumi MK and Tarun noted that even older individuals seek companionship and long-term relationships are often spotted at the community meet-ups. Online HIV matrimony portals offer some hope, but their reach is seemingly who helps facilitate such meet-ups, says, "Many people come from underprivileged backgrounds and aren't tech-savvy enough to maintain a profile. The emotional toll of living with HIV also means many don't always stay active on these platforms."Other social factors persist as well."Even within the HIV-positive community, people often seek partners from the same caste," Tarun added. "I once introduced two individuals from the Patil community, but the girl's parents insisted on the same sub-caste, and the match fell through."While stigma and practical hurdles remain, the journey of people living with HIV is no longer defined by fear or isolation. With stronger treatment options, growing awareness, and supportive communities, HIV-positive individuals are reclaiming their right to live, and love.- EndsMust Watch advertisement
